Treatment of Irritable Bowel Syndrome in Women

Gastroenterology Clinics of North America

Volumn 40, Issue 2, 2011, Pages 265-290

  Tsynman, Donald N ^a   Thor, Savanna ^a   Kroser, Joyann A ^b  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Irritable bowel syndrome; Treatment; Women

Indexed keywords

ALOSETRON; AMITRIPTYLINE; CELLULOSE; CITALOPRAM; DEXLOXIGLUMIDE; HEMICELLULOSE; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; INTERLEUKIN 10; INTERLEUKIN 12; LEUPRORELIN; LIGNIN; LINACLOTIDE; LUBIPROSTONE; NEPADUTANT; NEUROTROPHIN 3; PEPPERMINT OIL; PEXACERFONT; PLACEBO; PROBIOTIC AGENT; RENZAPRIDE; RIFAXIMIN; TEGASEROD; TIBOLONE; TONG XIE YAO FANG; TURMERIC; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANKLE FRACTURE; ANTERIOR CINGULATE; ANXIETY DISORDER; BACTERIAL OVERGROWTH; BIFIDOBACTERIUM LONGUM INFANTIS; CARDIOVASCULAR DISEASE; CHOLECYSTITIS; COGNITIVE THERAPY; COMORBIDITY; CONSTIPATION; DEFECATION URGENCY; DEPRESSION; DIARRHEA; DIET RESTRICTION; DIETARY FIBER; DIVERTICULITIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HEALTH CARE COST; HERBAL MEDICINE; HUMAN; HYPNOSIS; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; IRRITABLE COLON; ISCHEMIC COLITIS; LACTOBACILLUS SALIVARIUS; LOW DRUG DOSE; MENTAL DISEASE; MIGRAINE; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PNEUMONIA; PREMENOPAUSE; PREVALENCE; PROSTATE CANCER; REVIEW; SEX DIFFERENCE; SEX RATIO; SIDE EFFECT; TASTE AVERSION; UNSPECIFIED SIDE EFFECT; VOMITING;

FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; WOMEN'S HEALTH;

EID: 79956127237     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2011.03.012     Document Type: Review

References (153)

1. Spiller R., Aziz Q., Creed F., et al. Guidelines on the irritable bowel syndrome: mechanism and practical management. Gut 2007, 56:1770-1798.
2. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002, 97(Suppl 11):S1-S5.
3. Lee O.Y., Mayer E.A., Schmulson M., et al. Gender-related differences in IBS symptoms. Am J Gastroenterol 2001, 96:2184-2193.
4. Chang L., Heitkemper M.M. Gender differences in irritable bowel syndrome. Gastroenterology 2002, 123:1686-1701.
5. Shiotani A., Miyanishi T., Takahashi T. Sex differences in irritable bowel syndrome in Japanese university students. J Gastroenterol 2006, 41:562-568.
6. Nyrop K.A., Palsson O.S., Levy R.L., et al. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther 2007, 26:237-248.
7. Martin B.C., Ganguly R., Pannnicker S., et al. Utilization patterns and net direct medical cost to Medicaid of irritable bowel syndrome. Curr Med Res Opin 2003, 19:771-780.
8. Drossman D.A., Corazziari E., Delavaux M., et al. Rome III: the functional gastrointestinal disorders 2006, Degnon Associates, McLean (VA).
9. Mayer E.A., Berman S., Change L., et al. Sex-based differences in gastrointestinal pain. Eur J Pain 2004, 8:451-463.
10. Dalrymple J., Bullock I. Diagnosis and management of irritable bowel syndrome in adults in primary care: summary of NICE guidance. BMJ 2007, 336:556-558.
11. Spiller R. Clinical update: irritable bowel syndrome. Lancet 2007, 369:1586-1588.
12. Hayee B., Forgacs I. Psychological approach to managing irritable bowel syndrome. BMJ 2007, 334:1105-1109.
13. Drossman D.A. The functional gastrointestinal disorder and the Rome III process. Gastroenterology 2006, 130:1377-1390.
14. Saad R.J., Chey W.D. Recent developments in the therapy of irritable bowel syndrome. Expert Opin Investig Drugs 2008, 17:117-130.
15. Dom S.D., Palsson O.S., Thiwan S.I., et al. Increased colonic pain sensitivity in irritable bowel syndrome is the result of increased tendency to report pain rather than increased neurosensory sensitivity. Gut 2007, 156:1202-1209.
16. Naliboff B.F., Berman S., Chang L., et al. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 2003, 124:1738-1747.
17. Heitkemper M.M., Jarrett M. Pattern of gastrointestinal and somatic symptoms across the menstrual cycle. Gastroenterology 1992, 102:505-513.
18. Ouyang A., Wrzos H.F. Contribution of gender to pathophysiology and clinical presentation of IBS: should management be different in women?. Am J Gastroenterol 2006, 101:S602-S609.
19. Bainbridge E.T., Nicholas S.D., Newton J.R., et al. Gastrooesophageal reflux in pregnancy. Altered function of the barrier to reflux in asymptomatic women during early pregnancy. Scand J Gastroenterol 1985, 19:85-89.
20. Knight L.C., Parkman H.P., Brown K.L., et al. Delayed gastric emptying and decreased antral contractility in normal premenopausal women compared with men. Am J Gastroenterol 1997, 92:968-975.
21. Camilleri M. Serotonin in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes 2009, 16:53-59.
22. Talley N.J., Kellow J.E., Boyce P., et al. Antidepressant therapy (Imipramine and Citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci 2008, 53:108-115.
23. Morgan V., Pickens D., Gautam S., et al. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005, 54:601-607.
24. Halpert A., Dalton C.B., Diamant N.E., et al. Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 2005, 100:664-671.
25. Rajagopalan M., Kurian G., John J. Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 1998, 13:738-741.
26. Vahedi H., Merat S., Momtahen S., et al. Clinical trial: the effect of amitiptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008, 27:678-684.
27. Pimental M., Chow E.J., Lin H.C. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503-3506.
28. Pimental M., Chow E.J., Lin H.C. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003, 98:412-419.
29. Pimental M., Chatterjee S., Chow E.J., et al. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci 2006, 51:1287-1301.
30. Pimental M., Park S., Mirocha J., et al. The effect of a nonabsorbed oral antibiotic (Rifaximin) on the symptoms of the irritable bowel syndrome. Ann Intern Med 2006, 145:557-563.
31. Chang L., Ameen V.Z., Dukes G.E., et al. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005, 100:115-123.
32. Lembo T., Wright R.A., Bagby B., et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001, 96:2662-2670.
33. Chang L. Current perspectives in irritable bowel syndrome. Presented at the Fourth National Forum on Women's Issues in Gastroenterology and Hepatology. Philadelphia, June 4, 2010.
34. Krause R., Ameen V., Gordon S.H., et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007, 102:1709-1719.
35. Chey W.D., Chey W.Y., Heath A.T., et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004, 99:2195-2203.
36. Loughlin J., Quinn S., Rivero E., et al. Tegaserod and the risk of cardiovascular ischemic events. J Cardiovasc Pharmacol Ther 2010, 15(2):151-157.
37. Camilleri M., Chey W.Y., Mayer E.A., et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001, 161:1733-1740.
38. Camilleri M., Northcutt A.R., Kong S., et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000, 355:1035-1040.
39. Bardhan K.D., Bodemar G., Geldof H., et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000, 14:23-34.
40. Chey W.D., Pare P., Viegas A., et al. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Am J Gastroenterol 2008, 103:1217-1225.
41. Drossman D.A., Morris C.B., Hu Y., et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology 2005, 128:580-589.
42. Mearin F., Balboa A., Badia X., et al. Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype. Eur J Gastroenterol Hepatol 2003, 15:165-172.
43. Tack J., Muller-Lissner S., Bytzer P., et al. A randomized controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005, 54:1707-1713.
44. Novartis Pharmaceutical. Zelnorm [Online PDF]. Available at:, Archived 2007-04-10. Accessed December 30, 2010. http://www.zelnorm.com/Zelnrom_PR_US_330_Final_12_1007.pdf.
45. George A.M., Meyers N.L., Hickling R.I. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome: multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. Aliment Pharmacol Ther 2008, 27:830-837.
46. Alizyme pls Results from renzapride [Online Press-Release]. Available at:, Archived 2008-04-23. Accessed December 30, 2010. http://www.alizyme.com/alizyme/media/press/show.jsp%3fref%3d128.
47. Palomba S., Orio F., Manguso F., et al. Leuprolide acetate treatment with and without coadministration of tibolone in premenopausal women with menstrual cycle-related irritable bowel syndrome. Fertil Steril 2005, 83(4):1012-1019.
48. Tache Y., Monnikes H., Bonaz B., et al. Role of CRF in stress-related alterations of gastric and colonic motor function. Ann N Y Acad Sci 1993, 697:233-243.
49. Sweetser S., Camilleri M., Linker Nord S.J., et al. Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?. Am J Physiol Gastrointest Liver Physiol 2009, 296:1299-1306.
50. Marlett J.A., McBurney M.I., Slavin J.L. Position of the American Dietetic Association: health implications of dietary fiber. J Am Diet Assoc 2002, 102:993-1000.
51. Floch M.H., Narayan R. Diet in the irritable bowel syndrome. J Clin Gastroenterol 2002, 35(Suppl 1):S45-S52.
52. Spiller R.C. Pharmacology of dietary fibre. Pharmacol Ther 1994, 62:402-427.
53. Camilleri M., Heading R.C., Thompson W.G. Consensus report: clinical perspectives, mechanism, diagnosis and management of irritable bowel syndrome. Aliment Pharmacol Ther 2002, 16:1407-1430.
54. Bijkerk C.J., Muris J.W., Knottnerus J.A., et al. Systematic review: the role of different types of fiber in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004, 19:245-251.
55. Hebden J.M., Blackshaw E., D'Amato M., et al. Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and symptoms. Am J Gastroenterol 2002, 97:2315-2320.
56. Lanza E., Jones D.Y., Block E., et al. Dietary fiber intake in the US population. Am J Clin Nutr 1987, 46:790-797.
57. Bijkerk C.J., de Wit N.J., Stalman W.A., et al. Irritable bowel syndrome in primary care. The patients' and doctors' views on symptoms, etiology and management. Can J Gastroenterol 2003, 17:363-368.
58. Miller V., Lea R., Agrawal A., et al. Bran and irritable bowel syndrome: the primary-care perspective. Dig Liver Dis 2006, 33:737-740.
59. Lea R., Whowell P.J. The role of food intolerance in irritable bowel syndrome: the primary-care perspective. Dig Liver Dis 2006, 38:737-740.
60. Ford A.C., Talley N.J., Spiegel B.M., et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008, 337:a2313.
61. Lesbros-Pantoflickova D., Michetti P., Fried M., et al. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004, 20:1253-1269.
62. Brandt L.K., Bjorkman D., Fennerty M.B., et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002, 97:S7-S26.
63. Quartero A.O., Meineche-Schmidt V., Muris J., et al. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005, 2. CD003460.
64. Jailwala J., Imperiale T.H., Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000, 133:136-147.
65. Zuckerman M.J. The role of fiber in the treatment of irritable bowel syndrome: therapeutic recommendations. J Clin Gastroenterol 2006, 40:104-108.
66. Akehurst R., Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomized controlled trials. Gut 2001, 48:272-282.
67. Prior A., Whowell P.J. Double blind study of ispaghula in irritable bowel syndrome. Gut 1987, 28:1510-1513.
68. Kumar A., Kumar N., Vij J.C., et al. Optimum dosage of ispaghula husk in patients with irritable bowel syndrome: correlation of symptom relief with whole gut transit time and stool weight. Gut 1987, 28:150-155.
69. Villagrasa M., Boix J., Humbert P., et al. Aleatory clinical study comparing otilonium bromide with a fiber-rich diet in the treatment of irritable bowel syndrome. Ital J Gastroenterol 1991, 23(Suppl 1):67-70.
70. Fowlie S., Eastwood M., Prescott R. Irritable bowel syndrome: assessment of psychological disturbance and its influence on the response to fibre supplementation. J Psychosom Res 1992, 36:175-180.
71. Parisi G.C., Zilli M., Miani M.P., et al. High-fiver diet supplementation in patients with IBS: a multicenter, randomized open trial comparison between wheat bran diet and partially hydrolyces guar gum. Dig Dis Sci 2002, 47:1697-1704.
72. Burden S. Dietary treatment of irritable bowel syndrome: current evidence and guidelines for future practice. J Hum Nutr Diet 2001, 14:231-241.
73. Paineau D., Payen F., Panserieu D., et al. The effects of regular consumption of short-chain fructo-oligosacccharides on digestive comfort of subject with minor function bowel disorders. Br J Nutr 2008, 99:311-318.
74. Bernstein C.N. The placebo effect for gastroenterology: tool or torment. Clin Gastroenterol Hepatol 2006, 4:1302-1308.
75. Karamanolis G., Tack J. Nutrition and motility disorders. Best Pract Res Clin Gastroenterol 2006, 20:485-505.
76. O'Sullivan M.A., O'Morain C.A. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000, 32:294-301.
77. Sen S., Mullan M.M., Parker T.J., et al. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002, 47:2615-2620.
78. Nikfar S., Rahimi R., Rahimi F., et al. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 2008, 51:1776-1780.
79. Chadwick B., Chen W., Shu D., et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002, 123:1972-1979.
80. Gonsalkorale W.M., Perrey C., Pravica V., et al. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component?. Gut 2003, 52:91-93.
81. Barbara G., Stanghellini V., De Giorgio R., et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004, 126:693-702.
82. Maxwell P.R., Rink E., Kumar D., et al. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 2002, 97:104-108.
83. Johansson M.L., Molin G., Jeppsson B., et al. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Appl Environ Microbiol 1993, 59:15-20.
84. Pathmakanthan S., Li C., Cowie J., et al. Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed human colon. J Gastroenterol Hepatol 2004, 19:166-173.
85. O'Mahony L., McCarthy J., Kelly P., et al. Lactobacillus and Bifobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541-551.
86. Floch M.H. Use of diet and probiotic therapy in the irritable bowel syndrome. J Clin Gastroenterol 2005, 39:S243-S246.
87. Whorwell P.J., Altringer L., Morel J., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with IBS. Am J Gastroenterol 2006, 101:1581-1590.
88. McFarland L.V., Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008, 14:2650-2661.
89. Wilhelm S.M., Brubaker C.M., Varcak E.A., et al. Effectiveness of probiotics in the treatment of irritable bowel syndrome. Pharmacotherapy 2008, 28:496-505.
90. Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2008, 28:385-396.
91. Quigley E.M., Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 2007, 19:166-172.
92. Bundy R., Walker A.F., Middleton R.W., et al. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med 2004, 10:1015-1018.
93. Brinkhaus B., Hentschel C., Von Keudell C., et al. Herbal medicine with curcuma fumitory in the treatment of irritable bowel syndrome: a randomized, placebo-controlled, double-blind clinical trial. Scand J Gastroenterol 2005, 40:936-943.
94. Lacy B.E., Weiser K., Noddin L., et al. Irritable bowel syndrome: patients attitudes, concerns and level of knowledge. Aliment Pharmacol Ther 2007, 25:1329-1341.
95. Simren M., Mansson A., Langklide A.M., et al. Food-related gastrointestinal symptoms in irritable bowel syndrome. Digestion 2001, 63:108-115.
96. Halpert A., Dalton C.B., Palsson O., et al. What patients know about irritable bowel syndrome and what they would like to know. National survey on patient educational needs in IBS and development and validation of patient educational needs questionnaire (PEQ). Am J Gastroenterol 2007, 102:1972-1982.
97. Whitehead W.E., Drossman D.A. Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review. Am J Gastroenterol 2010, 105:814-820.
98. Whitehead W.E., Crowell M.D., Bosmajian L., et al. Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples. Gastroenterology 1990, 98:336-340.
99. Rees G.A., Davies G.I., Parker M., et al. Gastrointestinal symptoms and diet of members of an irritable bowel self-help group. J R Soc Health 1994, 114:182-187.
100. McKee A.M., Prior A., Whorwell P.J. Exclusion diets in irritable bowel syndrome: are they worthwhile?. J Clin Gastroenterol 1987, 9:526-528.
101. Faresjo A., Johansson S., Faresjo T., et al. Sex differences in dietary coping with gastrointestinal symptoms. Eur J Gastroenterol Hepatol 2010, 22:327-333.
102. Muller-lissner S.A., Kaatz V., Brandt W., et al. The perceived effect of various food and beverages on stool consistency. Eur J Gastroenterol Hepatol 2005, 17:109-112.
103. Saito Y.A., Locket G.R., Weaver A.L., et al. Diet and functional gastrointestinal disorders: a populations-based case-control study. Am J Gastroenterol 2005, 100:2743-2748.
104. Drossman D.A., Camilleri M., Mayer E.A., et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002, 123:2108-2131.
105. Koloski N.A., Talley N.J., Huskic S.S., et al. Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2003, 17:841-851.
106. Jarrett M.E., Heitkempre M.M., Hertig V., et al. Alternative health care practices in women with irritable bowel syndrome. Gastroenterology 1999, 116:A1012.
107. Kong S.C., Hurlstone D.P., Pocock C.Y., et al. The incidence of self-prescribed oral complimentary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol 2005, 39:138-141.
108. Shi K., Tong Y., Shen J.G., et al. Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: a systematic review. World J Gastroenterol 2008, 14:454-462.
109. Linde K., Berner M.M., Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008, 3. CD000448.
110. Franklin M., Chi J., McGavin C., et al. Neuroendocrine evidence for dopaminerfic actions of hypericum extract in healthy volunteers. Biol Psychiatry 1999, 46:581-584.
111. Gershon M.N., Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007, 132:397-414.
112. Jackson J.L., O'Malley P.G., Tomkins G., et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000, 108:65-72.
113. Saito Y.A., Rey E., Almazar-Elder A.E., et al. A randomized, double-blind, placebo-controlled trial of St. John's wort for treating irritable bowel syndrome. Am J Gastroenterol 2010, 105:170-177.
114. Kligler B., Chaudhary S. Peppermint oil. Am Fam Physician 2007, 75:1027-1030.
115. Hills J.M., Aaronson P.I. The mechanism of action of peppermint oil on gastrointestinal smooth muscle. Gastroenterology 1991, 101:55-65.
116. Cappello G., Spezzaferro M., Grossi L., et al. Peppermint oil in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis 2007, 39:530-536.
117. Liu J.H., Chen G.H., Yeh H.Z., et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997, 32:765-768.
118. Merat S., Khalili S., Mostajabi P., et al. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010, 55:1385-1390.
119. Pittler M.H., Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and meta-analysis. Am J Gastroenterol 1998, 98:1131-1135.
120. Spanier J.A., Howden C.W., Jones M.P. A systematic review of alternative therapies in the irritable bowel syndrome. Arch Intern Med 2003, 163:265-274.
121. Lawson M.J., Knight R.E., Tran K., et al. Failure of enteric-coated peppermint oil in the irritable bowel syndrome: a randomized double-blind crossover study. J Gastroenterol Hepatol 1988, 3:235-238.
122. Bian Z., Wu T., Liu L., et al. Effectiveness of the Chinese herbal formula tong xie yao fang for irritable bowel syndrome: a systematic review. J Altern Complement Med 2006, 12:401-407.
123. Bensoussan A., Talley N.J., Hing M., et al. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1999, 282:1585-1589.
124. Wang G., Li T.Q., Wang L., et al. Tong-xie-ning, a Chinese herbal formula, in treatment of diarrhea-predominant irritable bowel syndrome: a prospective, randomized, double-blind, placebo-controlled trial. Chin Med J (Engl) 2006, 119:2114-2119.
125. Leung W.K., Wu J.C., Liang S.M., et al. Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial. Am J Gastroenterol 2006, 101:1574-1580.
126. Hutton J.M. Issues to consider in cognitive-behavioral therapy for irritable bowel syndrome. Eur J Gastroenterol Hepatol 2008, 20:249-251.
127. Ross-Morris R., McAlpine L., Didsbury L.P., et al. A randomized controlled trial of a cognitive behavioral therapy-based self-management intervention for irritable bowel syndrome in primary care. Psychol Med 2010, 40:85-94.
128. Palsson O.S. Should we incorporate psychological care into the management of IBS?. Nat Clin Pract Gastroenterol Hepatol 2006, 3:474-475.
129. Drossman D.A., Toner B.B., Whitehead W.E., et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003, 125:19-31.
130. Boyce P.M., Talley N.J., Balaam B., et al. A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Am J Gastroenterol 2003, 98:2209-2218.
131. Kennedy T., Jones R., Darnley S., et al. Cognitive behavior therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomized controlled trial. BMJ 2005, 331:435.
132. Van Dulmen A.M., Fennis J.F., Bleijenberg G. Cognitive-behavioral group therapy for irritable bowel syndrome: effects and long-term follow-up. Psychosom Med 1996, 58:508-514.
133. Blanchard E.B., Lackner J.M., Sanders K., et al. A controlled evaluation of group cognitive therapy in the treatment of irritable bowel syndrome. Behav Res Ther 2007, 45:633-648.
134. Braid J. Practical essay on the curative agency of neuro-hypnotism 1843, J. Churchill Press, London.
135. Whorwell P.J., Prior A., Faragher E.B. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet 1984, 2:1232-1234.
136. Webb A.N., Kukuruzovic R.H., Catto-Smith A.G. Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2007, 4. CD005110.
137. Galovski T.E., Blanchard E.B. The treatment of irritable bowel syndrome with hypnotherapy. Appl Psychophysiol Biofeedback 1998, 23:219-232.
138. Palsson O.S., Turner M.J., Johnson D.A., et al. Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. Dig Dis Sci 2002, 47:2605-2614.
139. Roberts L., Wilson S., Singh S., et al. Gut-directed hypnotherapy for irritable bowel syndrome: piloting a primary care-based randomized controlled trial. Br J Gen Pract 2006, 56:115-121.
140. Wilson S., Maddison T., Roberts L., et al. Birmingham IBS Research Group. Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome. Aliment Pharmacol Ther 2006, 24:769-780.
141. Gholamrezaei A., Ardestani S.K., Emami M.N. Where does hypnotherapy stand in the management of irritable bowel syndrome? A systematic review. J Altern Complement Med 2006, 12:517-527.
142. Whitehead W.E. Hypnosis for irritable bowel syndrome: the empirical evidence of therapeutic effects. Int J Clin Exp Hypn 2006, 54:7-20.
143. Gonsalkorale W.M., Miller V., Afzal A., et al. Long term benefits of hypnotherapy for irritable bowel syndrome. Gut 2004, 52:1623-1629.
144. Gonsalkorale W.M., Houghton L.A., Whorwell P.J. Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness. Am J Gastroenterol 2002, 97:954-961.
145. Cremonini F., Camilleri M., McKinzie S., et al. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol 2005, 100:652-663.
146. Andresen V., Camilleri M., Busciglio I.A., et al. Effect of 5 days Linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007, 133:761-768.
147. Camilleri M., Bharucha A.E., Ueno R., et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006, 290:G942-G947.
148. Chai N., Dong L., Zong-Fang L., et al. Effects of neurotrophins on gastrointestinal myoelectric activities of rats. World J Gastroenterol 2003, 9(8):1874-1877.
149. Lecci A., Capriati A., Maggi C.A. Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome. Br J Pharmacol 2004, 141:1249-1263.
150. Sidhu R., McAlindon M.E., Leeds J.S., et al. The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome. J Gastrointestin Liver Dis 2009, 18(1):23-26.
151. Kilpatrick L.A., Ornitz E., Ibrahimovic H., et al. Sex-related differences in prepulse inhibition of startle in irritable bowel syndrome (IBS). Biol Psychol 2010, 84:272-278.
152. Cain K.C., Jarrett M.E., Burr R.L., et al. Gender differences in gastrointestinal, psychological, and somatic symptoms in irritable bowel syndrome. Dig Dis Sci 2009, 54:1542-1549.
153. Tack JF, Harris M, Proksch S, et al. AST-120 (spherical carbon adsorbent) improves pain and bloating in a randomized, double-blind, placebo-controlled trial in patients with non-constipating irritable bowel syndrome (IBS). Presented at Digestive Disease Week (DDW) 2010. New Orleans, May 1, 2010. Abstract S1298.